Small molecule Toll-like receptor 7 agonists localize to the MHC class II loading compartment of human plasmacytoid dendritic cells

Blood

Volumn 117, Issue 21, 2011, Pages 5683-5691

  Russo, Carla ^a   Cornella Taracido, Ivan ^b,d   Galli Stampino, Luisa ^a   Jain, Rishi ^b   Harrington, Edmund ^b   Isome, Yuko ^b   Tavarini, Simona ^a   Sammicheli, Chiara ^a   Nuti, Sandra ^a   Mbow, M Lamine ^c   Valiante, Nicholas M ^c   Tallarico, John ^b   De Gregorio, Ennio ^a   Soldaini, Elisabetta ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c Novartis Vaccines and Diagnostic   (United States)

^d Sanofi US   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5(6) CARBOXYTETRAMETHYLRHODAMINE; ALEXA FLUOR 488; ALPHA INTERFERON; B7 ANTIGEN; BAFILOMYCIN A1; CD63 ANTIGEN; CD86 ANTIGEN; FLUORESCENT DYE; HLA DR ANTIGEN; IMIQUIMOD; INTERLEUKIN 6; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RESIQUIMOD; SM 360320; TETRAMETHYLRHODAMINE; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CPG ISLAND; DRUG DISTRIBUTION; ENDOSOME; HUMAN; HUMAN CELL; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN LOCALIZATION; UPREGULATION;

EID: 79957590694     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-12-328138     Document Type: Article

References (44)

1. Isaacs A, Lindenmann J. Virus interference, I: the interferon. Proc R Soc Lond B Biol Sci. 1957;147(927):258-267.
2. Miller RL, Gerster JF, Owens ML, Slade HB, Tomai MA. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol. 1999;21(1):1-14. (Pubitemid 29097684)
3. Gester S, Wuest F, Pawelke B, Bergmann R, Pietzsch J. Synthesis and biodistribution of an 18F-labelled resveratrol derivative for small animal positron emission tomography. Amino Acids. 2005;29(4):415-428. (Pubitemid 41813496)
4. Hemmi H, Kaisho T, Takeuchi O, et al. Small antiviral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002;3(2):196-200. (Pubitemid 34141451)
5. Jurk M, Heil F, Vollmer J, et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848 [letter]. Nat Immunol. 2002;3(6):499. (Pubitemid 34669818)
6. Stanley MA. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol. 2002;27(7):571-577. (Pubitemid 35463873)
7. Kurimoto A, Ogino T, Ichii S, et al. Synthesis and structure-activity relationships of 2-amino-8-hydroxyadenines as orally active interferon inducing agents. Bioorg Med Chem. 2003;11(24):5501-5508. (Pubitemid 37464677)
8. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science. 2004;303(5663):1529-1531.
9. Forsbach A, Nemorin JG, Montino C, et al. Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses. J Immunol. 2008;180(6):3729-3738.
10. Chuang TH, Ulevitch RJ. Cloning and characterization of a sub-family of human toll-like receptors: hTLR7, hTLR8 and hTLR9. Eur Cytokine Netw. 2000;11(3):372-378. (Pubitemid 32268894)
11. Vollmer J, Weeratna R, Payette P, et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol. 2004;34(1):251-262. (Pubitemid 38111541)
12. Rutz M, Metzger J, Gellert T, et al. Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur J Immunol. 2004;34(9):2541-2550. (Pubitemid 39302811)
13. Latz E, Schoenemeyer A, Visintin A, et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol. 2004;5(2):190-198. (Pubitemid 38208361)
14. Latz E, Verma A, Visintin A, et al. Ligand-induced conformational changes allosterically activate Toll-like receptor 9. Nat Immunol. 2007;8(7):772-779. (Pubitemid 46965353)
15. Haas T, Metzger J, Schmitz F, et al. The DNA sugar backbone 2′ deoxyribose determines toll-like receptor 9 activation. Immunity. 2008;28(3):315-323. (Pubitemid 351335308)
16. Burgdorf S, Kautz A, Bohnert V, Knolle PA, Kurts C. Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. Science. 2007;316(5824):612-616. (Pubitemid 46683149)
17. Palucka K, Banchereau J, Mellman I. Designing vaccines based on biology of human dendritic cell subsets. Immunity. 2010;33(4):464-478.
18. Krieg AM, Vollmer J. Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. Immunol Rev. 2007;220:251-269. (Pubitemid 350045572)
19. Liu L, Botos I, Wang Y, et al. Structural basis of toll-like receptor 3 signaling with double-stranded RNA. Science. 2008;320(5874):379-381. (Pubitemid 351555661)
20. Bird PI, Trapani JA, Villadangos JA. Endolysosomal proteases and their inhibitors in immunity. Nat Rev Immunol. 2009;9(12):871-882.
21. Brinkmann MM, Spooner E, Hoebe K, Beutler B, Ploegh HL, Kim YM. The interaction between the ER membrane protein UNC93B and TLR3, 7, and 9 is crucial for TLR signaling. J Cell Biol. 2007;177(2):265-275. (Pubitemid 46658638)
22. Kim YM, Brinkmann MM, Paquet ME, Ploegh HL. UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes. Nature. 2008;452(7184):234-238. (Pubitemid 351380247)
23. Ewald SE, Lee BL, Lau L, et al. The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. Nature. 2008;456(7222):658-662.
24. Park B, Brinkmann MM, Spooner E, Lee CC, Kim YM, Ploegh HL. Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9. Nat Immunol. 2008;9(12):1407-1414.
25. Sepulveda FE, Maschalidi S, Colisson R, et al. Critical role for asparagine endopeptidase in endocytic Toll-like receptor signaling in dendritic cells. Immunity. 2009;31(5):737-748.
26. Barton GM, Kagan JC. A cell biological view of Toll-like receptor function: regulation through compartmentalization. Nat Rev Immunol. 2009;9(8):535-542.
27. Honda K, Ohba Y, Yanai H, et al. Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature. 2005;434(7036):1035- 1040. (Pubitemid 40586053)
28. Guiducci C, Ott G, Chan JH, et al. Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation. J Exp Med. 2006;203(8):1999-2008. (Pubitemid 44188473)
29. Gibson SJ, Lindh JM, Riter TR, et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol. 2002;218(1-2):74-86. (Pubitemid 36027092)
30. Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol. 2004;5(12):1219-1226. (Pubitemid 41057736)
31. Yoshimori T, Yamamoto A, Moriyama Y, Futai M, Tashiro Y. Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells. J Biol Chem. 1991;266(26):17707-17712. (Pubitemid 21907995)
32. Kadowaki N, Antonenko S, Lau JY, Liu YJ. Natural interferon alpha/beta-producing cells link innate and adaptive immunity. J Exp Med. 2000;192(2):219-226.
33. Metzelaar MJ, Wijngaard PL, Peters PJ, Sixma JJ, Nieuwenhuis HK, Clevers HC. CD63 antigen. A novel lysosomal membrane glycoprotein, cloned by a screening procedure for intracellular antigens in eukaryotic cells. J Biol Chem. 1991;266(5):3239-3245. (Pubitemid 21909200)
34. Eskelinen EL, Tanaka Y, Saftig P. At the acidic edge: emerging functions for lysosomal membrane proteins. Trends Cell Biol. 2003;13(3):137-145. (Pubitemid 36293786)
35. Shukla NM, Malladi SS, Mutz CA, Balakrishna R, David SA. Structure-activity relationships in human toll-like receptor 7-active imidazoquinoline analogues. J Med Chem. 2010;53(11):4450-4465.
36. Trombetta ES, Ebersold M, Garrett W, Pypaert M, Mellman I. Activation of lysosomal function during dendritic cell maturation. Science. 2003;299(5611):1400-1403. (Pubitemid 36254654)
37. Siebert GA, Hung DY, Chang P, Roberts MS. Ion-trapping, microsomal binding, and unbound drug distribution in the hepatic retention of basic drugs. J Pharmacol Exp Ther. 2004;308(1):228-235. (Pubitemid 38090722)
38. Sadaka C, Marloie-Provost MA, Soumelis V, Benaroch P. Developmental regulation of MHC II expression and transport in human plasmacytoid-derived dendritic cells. Blood. 2009;113(10):2127-2135.
39. Raposo G, Fevrier B, Stoorvogel W, Marks MS. Lysosome-related organelles: a view from immunity and pigmentation. Cell Struct Funct. 2002;27(6):443-456. (Pubitemid 36267713)
40. Young LJ, Wilson NS, Schnorrer P, et al. Differential MHC class II synthesis and ubiquitination confers distinct antigen-presenting properties on conventional and plasmacytoid dendritic cells. Nat Immunol. 2008;9(11):1244- 1252.
41. van den Hoorn T, Neefjes J. Activated pDCs: open to new antigen-presentation possibilities. Nat Immunol. 2008;9(11):1208-1210.
42. Sasai M, Linehan MM, Iwasaki A. Bifurcation of Toll-like receptor 9 signaling by adaptor protein 3. Science. 2010;329(5998):1530-1534.
43. Jaehn PS, Zaenker KS, Schmitz J, Dzionek A. Functional dichotomy of plasmacytoid dendritic cells: antigen-specific activation of T cells versus production of type I interferon. Eur J Immunol. 2008;38(7):1822-1832.
44. Marshansky V, Futai M. The V-type H+-ATPase in vesicular trafficking: targeting, regulation and function. Curr Opin Cell Biol. 2008;20(4):415-426.